Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nadia Abu-Nijmeh

Pediatrics Aurora, IL Medical Doctor

NPI 1972554533 CMS profile 316562

2121 Ridge Ave, Suite 101, Aurora, IL 60504

Open in the dashboard

General payments

$1,523

83 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nadia Abu-Nijmeh of Aurora, IL is reported in the CMS Open Payments database as having received $1,523 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $72 3
2024 General $325 16
2023 General $324 16
2022 General $160 9
2021 General $304 20
2020 General $139 9
2019 General $200 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nadia Abu-Nijmeh
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Nadia Abu-Nijmeh were reported at $72. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Nadia Abu-Nijmeh Pediatrics median Middle half National median
2019 $200 $86 $31–$183 $163
2020 $139 $49 $22–$110 $114
2021 $304 $68 $27–$158 $132
2022 $160 $77 $30–$173 $149
2023 $324 $88 $33–$190 $160
2024 $325 $94 $34–$206 $164
2025 $72 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $380 22 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $152 10 payments
  3. Pfizer Inc. $152 7 payments
  4. Supernus Pharmaceuticals, Inc. $150 8 payments
  5. Ironshore Pharmaceuticals Inc. $121 6 payments
  6. Sanofi Pasteur Inc. $100 5 payments
  7. Adlon Therapeutics L.P. $79 5 payments
  8. Cranial Technologies, Inc $79 5 payments
  9. GlaxoSmithKline, LLC. $60 3 payments
  10. Sanofi-Aventis U.S. LLC $51 2 payments
  11. Other $198 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,523 83 payments
Products named General payments · program years 2019–2025
  1. VAXELIS $334 19 payments
  2. GARDASIL 9 $295 18 payments
  3. VAXNEUVANCE $228 12 payments
  4. M-M-R II $224 12 payments
  5. PREVNAR 20 $132 6 payments
  6. COMIRNATY $132 6 payments
  7. VYVANSE $118 8 payments
  8. ROTATEQ $114 7 payments
  9. PROQUAD $110 6 payments
  10. Jornay PM 20mg capsules (Bottle of 100) $109 5 payments
  11. Other $1,305 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record